- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 31
- States / cities
- Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
- Conditions
- Migraine
- Interventions
- divalproex sodium
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Chronic Migraine
- Interventions
- Atogepant 30 mg, Atogepant 60 mg, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 35 more
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Migraine
- Interventions
- Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Migraine Disorders
- Interventions
- DaxibotulinumtoxinA
- Drug
- Lead sponsor
- Ki Health Partners. LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Stamford, Connecticut
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • San Diego, California • Ocoee, Florida + 15 more
- Conditions
- Episodic Migraine
- Interventions
- Dextromethorphan and quinidine, Placebo
- Drug
- Lead sponsor
- Cady, Roger, M.D.
- Individual
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
- Conditions
- Treatment for Prevention of Chronic Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 29
- States / cities
- Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more
- Conditions
- Migraine Disorders
- Interventions
- onabotulinumtoxinA, Topiramate
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more
- Conditions
- Migraine
- Interventions
- Melatonin, Placebo oral capsule
- Drug
- Lead sponsor
- Amy Gelfand
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Migraine, With or Without Aura
- Interventions
- Atogepant, Placebo-matching Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Migraine
- Interventions
- CEFALY
- Device
- Lead sponsor
- Cefaly Technology
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Migraine, Medication Overuse Headache
- Interventions
- Eptinezumab, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Winter Haven, Florida • Marrero, Louisiana • Springfield, Missouri + 3 more
- Conditions
- Intervention
- Interventions
- active neuromodulation for episodic migraine headache, placebo neuromodulation for episodic migraine headache
- Device
- Lead sponsor
- Scion NeuroStim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • West Palm Beach, Florida • Chicago, Illinois + 5 more
- Conditions
- Migraine Headache
- Interventions
- bupivicaine, normal saline, methylprednisolone, lidocaine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Migraine
- Interventions
- EVO756, Dose 1, EVO756, Dose 2, Placebo
- Drug
- Lead sponsor
- Evommune, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Buena Park, California • Fresno, California + 21 more
- Conditions
- Episodic Migraine
- Interventions
- Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Migraines, Bleeding, Spotting
- Interventions
- frovatriptan, placebo
- Drug
- Lead sponsor
- Scott and White Hospital & Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Frovatriptan, Menstrual Migraine
- Interventions
- Not listed
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,890 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
- Conditions
- Migraine
- Interventions
- Rimegepant, Various, No intervention
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 49 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York